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On a worldwide scale, colorectal cancer is one of the leading
causes of cancer deaths, affecting millions of people every
year. One third of colorectal cancer concerns the rectum. In
more than two thirds of the cases rectal cancer is still local-
ised to the pelvis without detectable metastases. In these
cases surgical resection is the cornerstone for a curative ap-
proach. Since the introduction of the combined abdomino-
perineal resection by Miles and Que´nu around the beginning
of the 20th century [1], rectal cancer became a curable dis-
ease. However, for many decades the results of surgery have
been disappointing, as it was often spoiled by a local recur-
rence rate of up to 40% or even higher. Uncontrolled progres-
sive local recurrences, hardly palliated by irradiation or
chemotherapy, have brought a miserable death to tens of mil-
lions of patients.
This situation lasted till the end of the last century when
the anatomical basis of rectal cancer surgery was revived by
Heald and Quirke [2,3]. Quirke demonstrated that the radial
margin between the tumour border and the surgical resection
margin was a strong prognosticator for local recurrence. He
pointed out that both tumour progression and surgical quality
were important for a safe margin. Poor surgery with incom-
plete mesorectum or tears into the mesorectal fat or muscu-
lar tube of the rectum could reduce this margin and
consequently lead to local recurrences. Heald introduced
the principle of total mesorectal excision (TME). In doing so
he defined the optimal quality of surgery.Worldwide surgeons have accepted as standard of care that
optimally the rectum has to be removed within its enveloping
mesorectal fascia. TME emphasises the importance of an ana-
tomical resection in the planes between the mesorectal fascia
and the surrounding pelvic fascias. However, the principle of
resection of the rectum within its mesorectal fascia seems to
fail when analysing low rectal cancer. From the early random-
ised controlled trials it was learned that patients requiring an
abdomino-perineal excision (APE) still had high positive cir-
cumferential resection margins [4–7]. The lower rectum and
anorectum are not surrounded by a protecting layer of meso-
rectal fat. Instead, already in an early stage, progressing tu-
mours reach and possibly infiltrate the pelvic floor muscles,
which are continuous with the external sphincter more dis-
tally. Compared with patients undergoing low anterior resec-
tion (LAR) APE patients have tumours located lower and more
advanced, therefore new principles of surgery had to be devel-
oped [8]. Results of lower rectal cancer surgery improved when
the principle of the extra levator approach was introduced [9–
12]. This involves removal of the lower rectum during an abdo-
mino-perineal excision en bloc with the external sphincter and
levator ani muscles. In the lower rectum the role of complete
removal of the mesorectal fascia is replaced by removal of
the levator ani muscles. Again, the quality of the surgery can
be judged by the completeness of this resection.
Modern rectal cancer surgery can be tailored to the specific
topographical relationships of the tumour. In proximal tu-
mours the mesorectal fascia acts as the guiding structure.
Transection of the specimen can be performed 4–5 cm distallys. Tel.: +31
E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 6 0 –7 1 61from the lower tumour border or at the pelvic floor when the
mesorectum terminates higher. More distal tumours can be
removed by either intersphincteric resection – if the tumour
is confined within the smooth muscle tube of the muscularis
propria, sometimes even allowing for a colo-anal anastomosis
– or extralevator resection if the pelvic floor is threatened or
already involved by tumour progression. The third option
for an abdomino-perineal excision is to take an even wider
approach, taking out the ischiorectal fat en bloc with the leva-
tor muscles, if the tumour has perforated or fistulated
through the pelvic floor muscles into this fatty area. However,
this will be the case only in extremely rare circumstances.
Modern rectal cancer surgery is part of a multidisciplinary
approach. Preoperative imaging with magnetic resonance
imaging (MRI) is able to delineate the tumour very accurately
and helps to select those patients requiring downsizing and
down-staging, optimising the chances of a good tumour
resection [13–15]. The pathologist plays an important role in
the feedback to the surgeon, which is necessary to improve
surgical outcome [16].
The first step in integration of optimal imaging, treatment
modalities and pathology is taken is several countries. The
next step will be to optimise treatment for the individual pa-
tient, who is interested not only in the oncological outcome
but also in functional results and subsequent quality of life.
Avoiding and decreasing morbidity, especially in the elderly,
will require the development of new innovative strategies.2. Contribution of pathology to the anatomical
approach
It may seem odd to start a discussion on modern surgical ap-
proaches to localised rectal cancer with the findings of the
pathologist. However, it was a pathologist who demonstrated
the importance of the distance of the radial tumour border to
the mesorectal fascia, which is called the circumferential
resection margin (CRM) in TME surgery [3].
In 2002 Nagtegaal analysed the data of the Dutch TME
study, and she confirmed that in 44% of the patients the in-
volved circumferential resection margin was the result of
poor-quality surgery. It was also shown that, after incomplete
mesorectal excision, the overall recurrence rate was almost
doubled, which could be attributed mainly to the excess of lo-
cal recurrences [16]. Nagtegaal and Quirke performed a meta-
analysis on the importance of the CRM in more than 17,500
patients and concluded that CRM involvement predicts not
only local recurrence but also distant metastasis and subse-
quent overall survival. Failure to achieve a negative CRM after
neoadjuvant treatment leads to a poorer prognosis compared
with no neoadjuvant treatment. Possibly the explanation for
this is the selection of patients with tumours more resistant
to therapy. This finding could be an argument for restaging
after neoadjuvant therapy, and to consider more prolonged
neoadjuvant treatment, or to refer to a specialised centre
for more extended resection or additional boosting of the area
at risk [17].
Thus, the actual feedback of the pathologist to the surgeon
should contain information on the CRM and quality of sur-
gery [18]. Another important issue, which will be discussed la-ter in this paper, is the evaluation of the effectiveness of the
chosen neoadjuvant treatment. Preferably, macroscopic
images of the resected specimens, as well as the microscopic
images, should be available for internal audit and continued
education and improvement of all member decisions during
the multidisciplinary tumour board meetings.
Quirke proposed a 3-point grading system for the evalua-
tion of the macroscopic specimen for both low anterior and
abdomino-perineal resections. Good surgery would be quali-
fied by an intact mesorectal fascia with only minor irregular-
ities, or in the case of APE, a specimen with levator ani and
external sphincters without any defects deeper than 5 mm
and the levator ani attached to the mesorectal fascia [19,20]
(see Figs. 1–3).
After moderate-quality surgery the bulk of the mesorec-
tum is removed but shows an irregular surface, however still
without exposing the muscularis propria or perforations. In
the case of an APE, a specimen which shows waist formation,
indicative for a less complete levator ani covering at the ano-
rectal junction, but with intact sphincters, signifies a moder-
ate quality of surgery.
Poor surgery would be characterised by severe irregulari-
ties on the surface of the specimen, exposing the muscularis
propria or internal sphincter or even showing perforations to
the lumen.
Very essential for the grading of the APE specimen is the
question of whether the levator ani muscle is still attached
to the mesorectum. Thus, waist formation is avoided and
the result is a more cylindrical resection. In order to achieve
optimal feedback, pathology reports should be standardised,
not only regarding the reporting of the TNM status, but also
on the quality of surgery [19].3. The importance of MRI for the surgical
treatment of rectal cancer
Magnetic resonance imaging (MRI) is a reliable diagnostic tool
for clinical staging of rectal cancer, but other imaging meth-
ods for the pelvis are also being used for this purpose. Com-
puted tomography (CT) is able to identify enlarged lymph
nodes, although it is not accurate for assessing the morphol-
ogy of these nodes. Furthermore, the contrast resolution of
CT is insufficient to reliably assess involvement of the surgical
resection plane in mid and lower rectal cancer. CT, however, is
indicated for distant staging of metastatic disease and, if
there is no easy access to an MRI, for assessment of resect-
ability of high rectal tumours [21–23]. Endorectal ultrasound
(EUS) cannot visualise the mesorectal fascia, but is the modal-
ity of choice to differentiate between T1 and T2 lesions for the
selection of local therapies. EUS has a high sensitivity to stage
depth of submucosal involvement [24]. However, MRI is the
king of kings of all imaging modalities in its tissue contrast
resolution and provides the necessary detailed anatomical
information on pelvic fascias and dissection planes between
pelvic soft tissues, which sets the scene for the planning of
the resection.
Without the anatomical topographical information of an
MRI, the surgeon has to rely on ad hoc decisions when unex-
pected problems occur during the actual surgical procedure
Fig. 1 – Rectal extralevator abdomino-perineal excision specimen. The solid yellow lines indicate the intact mesorectum. The
red lines demonstrate the extralevator muscles attached to the specimen covering widely the anorectal junction (white
arrow) where the mesorectum ends and the internal sphincter starts (dotted yellow line). Even advanced T3 or T4 tumours at
the anorectal junction and below can be safely removed when covered by the extralevator muscle layer. Typically a
cylindrically shaped specimen. Mesorectum intact. (For interpretation of the references to colour in this figure legend, the
reader is referred to the web version of this article.)
Fig. 2 – ‘Standard’ abdomino-perineal excision specimen, demonstrating waist formation at the anorectal junction or just
above (white arrow). Only marginal coverage by the external sphincters of the distal mesorectum. Will suffice for less
advanced tumours of the anorectum or anorectal junction. Specimen characterised by ‘waist’ formation. Mesorectum intact.
62 E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 6 0 –7 1and in a worst-case scenario these problems may even go
unnoticed, or have become irreversible. With the anatomical
information from MRI critical sites of resection can beanticipated and addressed before surgery: i.e. use of neoadju-
vant treatment or referral to a centre specialised in extended
extra anatomical pelvic resection if TME surgery is not justified.
Fig. 3 – Poor specimen after abdomino-perineal excision. Deep indentations and even perforation in mesorectum. Very little
coverage of the external sphincter and showing tears in the external sphincter.
E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 6 0 –7 1 63The Mercury study group reported the reliability of MRI
on predicting extramural depth of tumour invasion. Very
good correlation of extramural spread on MRI and histopa-
thology was found: the 95% confidence interval being
<0.5 mm. The TNM classification lacks specificity in the
T3 stage [25]. A T3 tumour with limited extramural spread
(outside the muscularis propria) has a different prognosis
to a T3 tumour with more extended spread. Merkel et al
demonstrated that a cut-off point of 5 mm spread divided
patients into groups with good and poor prognoses, pro-
vided that a safe CRM was obtained [26]. For the surgeon
it is important that patients with limited extramural
spread can be treated as T2 patients, and in most cases
will not require neoadjuvant treatment with its associated
adverse effect on surgical morbidity and functional
outcome.
Even more important from the surgical technical point of
view is the fact that MRI can reliably anticipate an involved
circumferential resection margin. MRI differentiates between
high-risk (<1 mm) and low-risk (>1 mm) patients for local
recurrence. MR CRM margins >1 mm and <2 mm, >2 and <5
and >5 mm carried a similar risk for local recurrence of
around 7%, in contrast to the 20% risk of patients with an
anticipated margin of <1 mm [27]. The ability to predict a 1-
mm free margin was recently confirmed by a German group
[28].
The ability of MRI to discriminate between positive and
negative lymph nodes is quite disappointing. Like other
imaging modalities, conventional MRI without any MR con-
trast lacks both sensitivity and specificity to identify or rule
out positive nodes, and cannot reliably be used for treatment
stratification [29,30]. Size has been an unreliable variable topredict nodal involvement [31,32]. Several contrast agents
have been and are under investigation, but at the time of
writing results are still inconclusive [33–35]. Diffusion-
weighted MRI imaging (DWI) shows a high signal in both be-
nign and malignant nodes and therefore cannot differentiate
between the two. A restaging MRI, including DWI, has a high
negative predictive value (NPV) for the detection of nodal
metastases and can be more reliably used for nodal restag-
ing after neoadjuvant treatment [36]. The most reliable vari-
able seems to be the evaluation of nodal morphology, such
as roundness, irregular border or heterogeneous texture.
However, this is difficult and subject to large inter-observer
variability, especially in nodes <6 mm and in patients with
only small nodes of limited value in clinical practices
[31,37]. MRI plays an important role in the evaluation of re-
sponse to neoadjuvant treatment (NT) and the consequences
for the final surgical resection. NT is able to downsize the tu-
mour. In particular, large tumours may have been over-
staged at the initial MRI.
Sometimes a pushing tumour border seen on primary
staging MRI may be mistaken for an infiltrating one.
Restaging with MRI after NT may reveal surgical dissection
planes which were obscured at the primary staging MRI. As
a consequence, surgical planning can be more
conservative.
Clinical T and N stage may also alter after NT and allow a
change in surgical approach. MRI is furthermore accurately
correlated with histopathological down-grading of the tu-
mour. Apart from opening new possibilities for a minimal
invasive surgical approach for the very good responders,
non-responders can be identified who may require intensifi-
cation of the treatment plan [38–44].
64 E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 6 0 –7 1In order to understand the consequences of NT, it is of cru-
cial importance that radiologists and pathologists participate
in the multidisciplinary treatment team.
4. Role of neoadjuvant treatment for the
surgeon
The primary objective in rectal cancer surgery is to achieve a
free surgical resection margin. The purpose of NT is twofold:
first, to sterilise the potential tumour-cell-bearing volume in
the pelvis, which is not removed during surgery, more specif-
ically the lateral zones of lymphatic spread; and second, to
change the size and stage of the primary rectal cancer in or-
der to facilitate surgical resection and even to allow for more
limited surgery. In Japan the lateral lymph nodes are removed
as standard procedure during rectal cancer surgery. By doing
so, NT can be safely omitted according to the Japanese work-
ers. Comparison between the Japanese results with extended
lymphadenectomy and the Dutch TME study (which random-
ised between TME surgery with and without 5 · 5 Gy preoper-
ative radiotherapy) showed that 5 · 5 with standard TME
surgery was as effective as extended lateral lymphadenec-
tomy for the prevention of local recurrences [45].
The Swedish Rectal Cancer Trials, the Dutch TME study
and the British CRO7 study have clearly demonstrated that
preoperative 5 · 5 Gy followed by immediate surgery (prefera-
bly within 1 week) yields excellent oncological results in pa-
tients in whom a CRM-negative margin can be achieved [46–
49]. A recent update of the third Swedish Rectal Cancer Trial
shows that a waiting period after 5 · 5 Gy short-course radio-
therapy effectively reduces postoperative morbidity, while
also a down-staging effect was noticed [50].
In contrast, advanced tumours, invading the mesorectal
fascia or even penetrating into the surrounding pelvic struc-
tures, would inevitably lead to positive surgical margins if
the surgeon sticks to the principle of dissection along the
mesorectal fascia. These patients require a more extended
resection, peripheral to the mesorectal fascia. In the pelvis
with organs packed tightly together these extended resec-
tions often result in loss of autonomic nerves, other pelvic
supporting structures (sacrum, pelvic floor muscles) or organs
(bladder, genital organs and ureters). Preoperative treatment
with radiotherapy and concomitant chemotherapy can effec-
tively downsize and even down-stage locally advanced tu-
mours and thus take away the threat of an involved margin,
allowing for a more preservative approach [51–53]. Whereas
the lateral margin is influenced by NT, it is not evident that
the distal margin moves upwards, or that it is possible or even
wise to perform a low anastomosis in a previously irradiated
part of the (ano-)rectum [54,55].
SystemicchemotherapymayalsobeincorporatedintoanNT
scheme. In metastasised patients it helps to select the respond-
ers, who may be good candidates for metastasectomy aswell as
resection of the primary from those patients who are progres-
sive and would not benefit from extended surgery [56]. The
Dutch Colorectal Cancer Group initiated the international RAP-
IDO study, which seeks to find answers for the question of
whether upfront systemic chemotherapy as part of NT can re-
ducetheoccurrenceofmetastasesinlocalisedrectalcancer[57].5. The anatomical surgical approach to
localised rectal cancer
The surgical approach is based on the preoperative MRI image
and may also take into account the response to neoadjuvant
treatment. The resection itself follows anatomical principles
and is based on removal of the rectum within its covering
mesorectal fascia. In proximal tumours, the distal rectum
may be preserved, provided that at least 4–5 cm of the meso-
rectum is removed distally from the tumour [58]. In low rectal
cancers at the anorectal junction or below, depending on the
infiltration depth of the tumour, the pelvic floor muscles and
external sphincter often need to be removed en bloc with the
rectum to assure a complete resection with a CRM of more
than 1 mm [10,11].
A secondary objective is to avoid damage to the nerve
system as little as possible. The pelvic autonomic nerves
consist of a fine network originating around the aorta,
which descends as a fine mesh lining the mesorectal fascia.
The hypogastric nerves condense and split into two lateral
bundles which can easily be identified and followed to the
inferior hypogastric plexus. In this area innervation, lym-
phatic drainage and blood supply mingle in the lateral pil-
lars of the rectum. The nervi erigentes also join the
inferior hypogastric plexus from the dorsolateral and also
lie in close approximation to the dorsolateral mesorectal
fascia. The somatic levator ani and pudendal nerves are
protected by the pelvic fascia and are less at risk than the
autonomic nerves [59].
The anterior mesorectum distally to the peritoneal
reflection is thin, but, similarly to the rest of the mesorec-
tum, is also covered with a fascia-like structure (fascia of
Denonvilliers), which allows for dissection of the anterior
mesorectal fascia from the prostate/vesicles or posterior
vaginal wall [60,61]. More distally, this layer ends and is re-
placed by intertwining bundles of somatic perineal muscles
joining with the smooth muscular layer of the muscularis
propria of the anorectum. This organisation of muscle fibres
anchors the anorectum to the pelvis. More laterally and
dorsally at the level of the sphincters, the adherence of
the smooth muscles to the surrounding external sphincter
muscles is much more loosely organised. The external
sphincter may be considered the distal part of the funnel
shaped pelvic floor muscles enveloping the smooth-muscu-
lar layer of the internal sphincter. As mentioned above, lat-
erally and dorsally the adherence between internal and
external sphincters is low and allows for the development
of an intersphincteric resection plane. On the anterior side
the somatic pelvic floor muscles, which distally join in a
tendinous perineal body, are very adherent to the anterior
part of the anal rectum. Therefore no such thing as an
intersphincteric dissection plane is present on the anterior
side of the distal rectum [62]. This is a very important ana-
tomical fact which influences the way low rectal tumours
can be dissected. An abdomino-perineal excision (APE) can
be performed in three dissection planes: (1) the intersphinc-
teric plane which is close to the internal sphincter and suit-
able only for tumours which are confined to the muscularis
propria of the rectum; (2) the extralevator plane which
Fig. 4 – Early 19th century anatomical lithography demonstrating the intense autonomous nerve network in the abdomen,
illustrating the high risk of surgery to damage the nerves. Furthermore the levator ani muscle can be seen as an envelope
around the distal rectum.
E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 6 0 –7 1 65follows the external fascia of the external sphincter contin-
uously along the external fascia of the levator ani muscles
and transects these muscles as laterally as possible before
entering the abdomen; and (3) the ischiorectal plane which
also removes the ischiorectal fat and which follows the
external fascia of the pelvis, removing the ischiorectal fat
en bloc with the levator ani muscles. Again, the abdomen
is entered as laterally as possible at the level of the attach-
ment of the levator ani muscles to the pelvic wall see
(Fig. 4).
In most distal rectal carcinomas the extralevator abdomi-
no-perineal excision (ELAPE) is recommended to achieve a
complete resection with a negative CRM [63]. Either the pa-
tient may be operated in a supine position with the legs in
movable stirrups, or the patient may be turned to prone posi-
tion for the perineal resection [64]. When the operation is per-
formed in the supine position the patient does not need to be
turned and the procedure can start with either the perineal
phase or the abdominal phase.
In the supine position the dissection starts with an inci-
sion around and subsequent closure of the anus [10,19]
(Fig. 5). The external perineal fascia which covers the external
sphincter can be followed up to the lateral attachment of the
levator ani to the pelvic sidewall. At this level the levator ani
can be cut, exposing the mesorectum. Dorsally, the anococ-
cygeal ligament has to be transected. Depending on the loca-
tion of the tumour, the presacral space may be entered
ventrally to the coccyx, or in dorsally located tumours, the
coccyx may be removed to enter the presacral space. After
transection of the levator on both sides, exposing the meso-
rectum and opening the presacral space exposing the dorsal
part of the distal mesorectum, the anterior dissection maycommence. The anterior part of the levator ani muscle en-
closes the internal genital organs and needs to be transected
at the level of Denonvilliers’ fascia. After exposing Denonvil-
liers’ fascia the dissection continues distally; retracting the
specimen dorsally helps to identify the somatic perineal mus-
cles, which are closely adherent to the anorectum. The tran-
section takes place in the somatic muscles, avoiding a
fausse route into the bowel. If the operation was not started
with the abdominal phase, the abdomen is opened now. Dis-
section is according to TME principles, avoiding nerve dam-
age. As the pelvic floor muscles are already transected,
taking out the specimen is a relatively uncomplicated
procedure.
If the operation is performed in prone position, the proce-
dure most often starts with the abdominal phase, with the
patient lying in supine position [65] (Fig. 6). Again, care must
be taken not to push the dissection too deep down because of
the risk of coning in, resulting in dissection of the pelvic floor
off the mesorectum and subsequent waist formation. How-
ever, it is important to develop the presacral space until the
os coccygis is exposed. On the lateral side the low hypogastric
plexus has to be dissected off the mesorectum and the lateral
pillars also have to be transected. Denonvilliers’ fascia has to
be exposed before the abdominal phase can be ended and the
patient can be turned into prone position for the perineal
phase.
In prone position a teardrop like incision is made around
the anal skin and extended proximally above the ano-coccy-
geal joint. After closure of the anus, the deep perineal fascia
is followed from the external sphincter to the lateral attach-
ments of the levator ani. After the coccyx has been cut, the al-
ready opened presacral space is entered and the lateral
Fig. 5 – Perineal phases of an extralevator abdomino-perineal excision in supine position. mr, mesorectum; pb, perineal body.
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level of Denonvilliers’ fascia, the specimen can be everted
through the perineal wound and the dissection of the anterior
plane of the specimen commences under direct vision. First,
the puborectal sling has to be cut, as also the deep perineal
muscles which are closely adherent to the anterior part of
the anorectum. Again the dissection is carried out proximally
to distally. Cutting the perineal body is the last part of the
operation before the specimen is taken out. Care must be ta-
ken not to damage the urethra and the neural bundles of
Walsh, which are very close to this dissection plane.
In both positions a complete extralevator abdomino-peri-
neal excision can be performed. In prone position visibility
of the perineal operating field is better at the cost of a wider
incision, which requires closure with a (biological) mesh or
musculo-cutaneous flap [9]. In the supine position simulta-
neous access to the tumour from the abdomen and perineum
may be an advantage in more advanced tumours. An inter-
sphincteric or ischiorectal approach is more commonly per-
formed in supine position. In both positions, the abdominal
phase may also be performed laparoscopically.6. Future perspectives
6.1. Registry
On a population-based level, outcome of rectal cancer treat-
ment differs not only widely among countries, but also within
countries among hospitals and even within hospitals among
individual surgeons [18,66–68]. But in the end, the chain of
treatments given to an individual patient can be traced back
to each individual link of the chain. If the quality of pathology
is excellent, it will enable one to unravel the different prog-
nostic variables which apply to an individual patient. Not only
can the biology of the tumour be ascertained but also the
quality of surgery and the effect of neoadjuvant treatment.
Furthermore the anatomical information from the MRI may
be linked to the outcome and quality of the surgical
procedure.
Registration of these variables will identify the weak links
and will allow better quality of the complete chain, improving
outcome and reducing the burden of treatment costs for
avoidable poor results [69] (Fig. 7).
Fig. 6 – Perineal phases of an extralevator abdomino-perineal excision in prone position. La, levator ani muscle; vs, vesiculea
seminales; zb, nerve bundles of Walsh.
E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 6 0 –7 1 67Localised rectal cancer – but also metastasised rectal can-
cer – must be treated by a multidisciplinary team. In order to
achieve the best quality of treatment, the planning of the
treatment and the sequence of the different treatment
modalities have to be decided upon before any treatment is
given. During a multidisciplinary team meeting (MDT), after
the results of imaging and histopathological biopsies have be-
come available, the specific problems of a rectal cancer can be
identified and the best approach for the individual patient
may be selected, depending on the presence/exclusion of
metastatic disease, local extent of the tumour and the pa-
tient’s condition. It is important for the patient to know
who has the role of the director of the treatment. In most
cases this responsibility lies with the surgeon, who is respon-
sible not only for the surgery but for all components involved
in the treatment planning.
On a local level the use of standard protocols, the registra-
tion of the MDT meetings and the registration of the impor-
tant outcome parameters can help to identify blind spots.
These data can constitute the basis for a larger – possibly na-
tional – registry [70]. These national registries can be used to
compare countries. In Norway, Sweden, Denmark, the UK andthe Netherlands mandatory registration has led to almost
100% coverage of the population.
EUROCARE collects colorectal cancer data from all Euro-
pean countries and was able to show large differences in out-
come in Europe [66].
A limitation on the overall use of the EUROCARE database
is the wide spread in coverage of their populations between
the European countries. It is difficult to compare results be-
tween countries with coverage of less than 50% and countries
with coverage of 100%. Furthermore, the completeness of
important clinical data such as stage distribution and cancer
subsites varies widely between registries. For example, the
United Kingdom had poorer oncological results than France
and Germany; however, the UK has coverage of 100% com-
pared with coverage of 18% and 1% respectively for France
and Germany. Explaining difference in outcome between
countries with different coverage is difficult, particularly
when it is unclear whether coverage of less than 50% is repre-
sentative for the country as a whole.
But then again, there is no need to create a scale of the
outcome of different countries. It is more relevant to identify
the best practice and to set European guidelines based on the
Fig. 7 – Good collaboration of radiologist, surgeon and pathologist enables continuous quality improvement. Good
registration is an indispensable prerequisite (http://www.virtualpathology.leeds.ac.uk)
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ject, which promotes registry based on consensus and subse-
quent sharing of data, can lead to a better outcome for rectal
cancer patients all over the world [66,73–76].
6.2. Centralisation
With the improvement in care during the last decades and the
introduction of MDT meetings, the oncological outcome of
rectal cancer has greatly improved. Another more recent
development and improvement in cancer care is the introduc-
tion of centralisation of care for advanced cases and major
surgery. In rectal cancer this also plays an important role. In
advanced cases the cancer grows through its surrounding fas-
cia into other organs and structures. In those advanced cases,
when an exenteration is needed, the resection could consist
of an orthopaedic, gynaecological and urological en bloc
resection combined with the rectal resection. It is not desir-
able that such a procedure is performed by multiple surgeons.
Therefore the rectal cancer surgeon has to be a complete pel-
vic surgeon. However, normally these advanced cases have a
low incidence in a normal regional hospital. The small num-
bers increase the risk of performing an irradical resection as
the experience with these cases is limited. Centralisation of
advanced rectal cancer cases will not only result in less irrad-
ical resections but also in better postoperative care. As a hos-
pital treats more advanced cases, all specialties involved in
rectal cancer care gain more experience. Furthermore postop-
erative complications are seen sooner, radiological imaging is
interpreted better by the radiologist and pathologists gain
more experience with large specimens and the influence of
neoadjuvant treatment. All this will result in lower mortalityrates and better oncological outcome. Specialisation has led
to improved outcome in rectal cancer treatment; how much
more this will be true for locally advanced cases requiring
more individualised surgery [77–79].
6.3. Patient reported outcome measures
Due to the major improvements in therapy and oncological
outcome in the last decades, the influence of treatment on
the individual patient has become more and more important.
Particularly in the last decade, where outcome of a disease is
not the only measurement of adequate treatment, there is an
increasing interest in the influence of treatment on patients’
quality of life (QOL). Most of the studies published on quality
of life and rectal cancer use generally used questionnaires
such as the sf-36, EORTC QLQ-C30 OR EORTC QLQ-C38. These
questionnaires are reliable, valid and responsive, but have not
been developed to assess treatment on an individual level
[80–82].
The modern rectal cancer patient is confronted with a
combination of treatments, all of which will to a certain ex-
tent influence his way of living. The patient would probably
like to be informed about alternatives in their treatment sche-
dule and about the consequences of their choice.
It is important for future research to focus on different and
more interesting patient groups, such as frail and elderly pa-
tients. In these patients, it is more likely that the assumed
benefits of survival give an increase in morbidity and could
have an adverse effect on QOL. Future studies on rectal cancer
have not only to focus on the effect of additional treatments
on survival, but also the influence of the treatment on QOL.
If the treatment results in increase in QOL, is the possible
E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 6 0 –7 1 69consequent decrease in QOL worthwhile? It is likely that
these studies will make the decision process easier for the in-
volved specialties in the treatment of rectal cancer and will
result in a more patient-tailored treatment.
7. Conclusion
Surgery is still the cornerstone of rectal cancer treatment for
the time being. Therefore, the surgeon should take the role of
the director of the treatment plan, and should realise that sur-
gery is an integral part of a comprehensive multidisciplinary
approach. The basis for quality assurance is registration. A
modern anatomical surgical approach requires also a modern
attitude towards quality assurance and an obligation to keep
the patient well informed about the choices which have been
made and to allow the patient to have his/her own say in the
matter.
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